Global Epidemiology of Hepatocellular Carcinoma
- PMID: 39659901
- PMCID: PMC11626783
- DOI: 10.1016/j.jceh.2024.102446
Global Epidemiology of Hepatocellular Carcinoma
Abstract
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and a significant global health challenge due to its high mortality rate. The epidemiology of HCC is closely linked to the prevalence of chronic liver diseases, the predominant etiology being hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, alcohol consumption, and metabolic disorders such as metabolic dysfunction-associated steatotic liver disease (MASLD). HCC incidence varies widely globally, with the highest rates observed in East Asia and sub-Saharan Africa. This geographic disparity is largely attributed to the endemicity of HBV and HCV in these regions. In Western countries, the incidence of HCC has been rising, driven by increasing rates of alcohol abuse and the presence of steatosis liver disease. MASLD-associated HCC has a higher body mass index, a higher rate of type 2 diabetes mellitus, hyperlipidemia, hypertension, and association with cardiovascular diseases. Steatosis-associated HCC is also known to develop in the absence of cirrhosis, unlike alcohol-related liver disease and viral hepatitis. Prevention strategies vary by region, focusing on vaccination against HBV, antiviral treatments for HBV and HCV, alcohol moderation, and lifestyle interventions along with weight reduction to reduce obesity and incidence of MASLD-related HCC incidence.
Keywords: asia; global epidemiology; hepatocellular carcinoma; india.
© 2024 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
None.
Similar articles
-
NIH Consensus Statement on Management of Hepatitis C: 2002.NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46. NIH Consens State Sci Statements. 2002. PMID: 14768714
-
Trends in Hepatocellular Carcinoma Mortality Rates in the US and Projections Through 2040.JAMA Netw Open. 2024 Nov 4;7(11):e2445525. doi: 10.1001/jamanetworkopen.2024.45525. JAMA Netw Open. 2024. PMID: 39556395 Free PMC article.
-
Epidemiology of Hepatocellular Carcinoma in India - An Updated Review for 2024.J Clin Exp Hepatol. 2024 Nov-Dec;14(6):101447. doi: 10.1016/j.jceh.2024.101447. Epub 2024 May 21. J Clin Exp Hepatol. 2024. PMID: 38957612 Review.
-
Hepatocellular carcinoma in patients without cirrhosis.World J Gastroenterol. 2025 Jun 21;31(23):107100. doi: 10.3748/wjg.v31.i23.107100. World J Gastroenterol. 2025. PMID: 40575339 Free PMC article. Review.
-
The Midlands Liver Research Alliance - A partnership to optimise obesity-related liver disease research: targeting areas of high incidence and underserved communities.NIHR Open Res. 2024 Dec 12;4:75. doi: 10.3310/nihropenres.13784.1. eCollection 2024. NIHR Open Res. 2024. PMID: 40547821 Free PMC article.
Cited by
-
Casein Kinase 2α Ablation Confers Protection Against Metabolic Dysfunction-Associated Steatotic Liver Disease: Role of FUN14 Domain Containing 1-Dependent Regulation of Mitophagy and Ferroptosis.MedComm (2020). 2025 Jul 11;6(7):e70277. doi: 10.1002/mco2.70277. eCollection 2025 Jul. MedComm (2020). 2025. PMID: 40656543 Free PMC article.
-
Transient hepatic intensity differences: correlations with treatment outcomes and adverse events following DEB-TACE in hepatocellular carcinoma.Insights Imaging. 2025 Aug 1;16(1):164. doi: 10.1186/s13244-025-02041-2. Insights Imaging. 2025. PMID: 40750947 Free PMC article.
-
Predictors of Non-response to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma: A Multicentre Real World Study (HCC-AB Study).J Clin Exp Hepatol. 2025 Jul-Aug;15(4):102513. doi: 10.1016/j.jceh.2025.102513. Epub 2025 Feb 8. J Clin Exp Hepatol. 2025. PMID: 40129631
-
Mitochondrial alterations and signatures in hepatocellular carcinoma.Cancer Metastasis Rev. 2025 Feb 18;44(1):34. doi: 10.1007/s10555-025-10251-9. Cancer Metastasis Rev. 2025. PMID: 39966277 Free PMC article. Review.
-
Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends.Hum Vaccin Immunother. 2025 Dec;21(1):2540143. doi: 10.1080/21645515.2025.2540143. Epub 2025 Aug 17. Hum Vaccin Immunother. 2025. PMID: 40820303 Free PMC article.
References
-
- Kumar A., Acharya S.K., Singh S.P., et al. The Indian national association for study of the liver (INASL) consensus on prevention, diagnosis and management of hepatocellular carcinoma in India: the puri recommendations. J Clin Exp Hepatol. 2014;4(suppl 3):S3–S26. doi: 10.1016/j.jceh.2014.04.003. - DOI - PMC - PubMed
-
- Kumar A., Acharya S.K., Singh S.P., et al. 2019 update of Indian national association for study of the liver consensus on prevention, diagnosis, and management of hepatocellular carcinoma in India: the puri II recommendations. J Clin Exp Hepatol. 2020;10:43–80. doi: 10.1016/j.jceh.2019.09.007. - DOI - PMC - PubMed
-
- Kumar A., Acharya S.K., Singh S.P., et al. 2023 Update of Indian national association for study of the liver consensus on management of intermediate and advanced hepatocellular carcinoma: the puri III recommendations. J Clin Exp Hepatol. 2024;14: doi: 10.1016/j.jceh.2023.08.005. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources